Akebia Therapeutics, Inc.

NASDAQ:AKBA

3.56 (USD) • At close July 25, 2025
Bedrijfsnaam Akebia Therapeutics, Inc.
Symbool AKBA
Munteenheid USD
Prijs 3.56
Beurswaarde 934,984,160
Dividendpercentage 0%
52-weken bereik 1.07 - 4.079
Industrie Biotechnology
Sector Healthcare
CEO Mr. John P. Butler MBA
Website https://www.akebia.com

An error occurred while fetching data.

Over Akebia Therapeutics, Inc.

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent

Vergelijkbare Aandelen

Orgenesis Inc. logo

Orgenesis Inc.

ORGS

2.6 USD

DiaMedica Therapeutics Inc. logo

DiaMedica Therapeutics Inc.

DMAC

5.05 USD

Streamline Health Solutions, Inc. logo

Streamline Health Solutions, Inc.

STRM

5.305 USD

InflaRx N.V. logo

InflaRx N.V.

IFRX

0.899 USD

Novo Integrated Sciences, Inc. logo

Novo Integrated Sciences, Inc.

NVOS

0.003 USD

MediWound Ltd. logo

MediWound Ltd.

MDWD

20.33 USD

Rain Therapeutics Inc. logo

Rain Therapeutics Inc.

RAIN

3.724 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)